secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2023-09-01T23:59:59+00:00
Accession:  0001193125-23-227647
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO enters into $150M ATM equity offering agreement with BofA Securities
------------------------------------------------------------------------------

- May offer and sell common stock up to $150M aggregate price under ATM Sales Agreement with BofA Securities.
- Agent will receive commission up to 3% of gross proceeds; sales made at prevailing market prices.
- Company not obligated to sell any shares; agreement may terminate at any time by either party.
- Offering complements existing S-3 shelf registration filed December 30, 2022.
- BofA has provided and may continue providing investment banking and financial services to REGENXBIO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312523227647/0001193125-23-227647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312523227647/d548812d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-227647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer